# Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients

> **NCT02762084** · PHASE2 · COMPLETED · sponsor: **PellePharm, Inc.** · enrollment: 17 (actual)

## Conditions studied

- Basal Cell Nevus Syndrome

## Interventions

- **DRUG:** Patidegib
- **DRUG:** Vehicle gel

## Key facts

- **NCT ID:** NCT02762084
- **Lead sponsor:** PellePharm, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-06
- **Primary completion:** 2017-04-24
- **Final completion:** 2017-04-24
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2020-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02762084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02762084, "Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02762084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*